Mitochondrial and Oxidative Stress Response in HepG2 Cells Following Acute and Prolonged Exposure to Antiretroviral Drugs

Journal of Cellular Biochemistry

Volumn 116, Issue 9, 2015, Pages 1939-1946

  Nagiah, Savania ^a   Phulukdaree, Alisa ^b   Chuturgoon, Anil ^a  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

mtDNA; NRTI; NUCLEAR ERYTHROID 2 RELATED FACTOR 2; OXIDATIVE STRESS; PGC 1

Indexed keywords

ADENOSINE TRIPHOSPHATE; MITOCHONDRIAL DNA; REACTIVE OXYGEN METABOLITE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTIRETROVIRUS AGENT;

ANTIOXIDANT ACTIVITY; ARTICLE; BIOGENESIS; CELL FUNCTION; CELLULAR STRESS RESPONSE; DNA INTEGRATION; DRUG EXPOSURE; DRUG MECHANISM; HEPG2 CELL LINE; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRION; OXIDATIVE STRESS; PRIORITY JOURNAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL;

ANTI-RETROVIRAL AGENTS; DNA, MITOCHONDRIAL; GENE EXPRESSION REGULATION; HEP G2 CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

EID: 84937460071     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.25149     Document Type: Article

References (39)

1. Abraham P, et al., 2013. Depletion of the cellular antioxidant system contributes to tenofovir disoproxil fumarate-induced mitochondrial damage and increased oxido-nitrosative stress in the kidney. J Biomed Sci 20: 1-15.
2. Banerjee A, et al., 2013. Zidovudine (AZT) and hepatic lipid accumulation: Implication of inflammation, oxidative and endoplasmic reticulum stress mediators. PLoS ONE 8: e76850.
3. Bienstock RJ, Copeland WC, 2004. Molecular insights into NRTI inhibition and mitochondrial toxicity revealed from a structural model of the human mitochondrial DNA polymerase. Mitochondrion 4: 203-213.
4. Birkus G, et al., 2002. Assessment of mitochondrial toxicity in human cells treated with tenofovir: Comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46: 716-723.
5. Bleeker-Rovers CP, et al., 2000. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient. Neth J Med 57: 190-193.
6. Brinkman K, et al., 1998. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 12: 1735-1744.
7. Carr A, Cooper D A,. 2000. Adverse effects of antiretroviral therapy. Lancet 356: 1423-1430.
8. Celum C, Baeten J,. 2012. Tenofovir-based pre-exposure prophylaxis for HIV prevention: Evidence and evolving questions. Curr Opin Infect Dis 25: 51.
9. Chuturgoon AA, et al., 2014. Fumonisin B1 modulates expression of human cytochrome P450 1b1 in human hepatoma (Hepg2) cells by repressing Mir-27b. Toxicol Lett 227: 50-55.
10. Cihlar T, et al., 2002. Tenofovir exhibits low cytotoxicity in various human cell types: Comparison with other nucleoside reverse transcriptase inhibitors. Antivir Res 54: 37-45.
11. Cohen BH,. 2010. Pharmacologic effects on mitochondrial function. Dev Disabil Res Rev 16: 189-199.
12. Dagan T, et al., 2002. Mitochondrial dysfunction and antiretroviral nucleoside analog toxicities: What is the evidence. Mitochondrion 1: 397-412.
13. de Baar MP, et al., 2007. Effects of apricitabine and other nucleoside reverse transcriptase inhibitors on replication of mitochondrial DNA in HepG2 cells. Antivir Res 76: 68-74.
14. Igoudjil A, et al., 2007. High doses of stavudine induce fat wasting and mild liver damage without impairing mitochondrial respiration in mice. Antivir Ther 12: 389.
15. Kline E, et al., 2009. Long-term exposure to AZT, but not d4T, increases endothelial cell oxidative stress and mitochondrial dysfunction. Cardiovasc Toxicol 9: 1-12.
16. Kohler JJ, et al., 2009. Tenofovir renal toxicity targets mitochondria of renal proximal tubules. Lab Invest 89: 513-519.
17. Lebrecht D, et al., 2009. Mitochondrial tubulopathy in tenofovir disoproxil fumarate-treated rats. J Acquir Immune Defic Syndr 51: 258-263.
18. Lewis W, et al., 2001. Mitochondrial DNA depletion, oxidative stress, and mutation: Mechanisms 0f dysfunction from nucleoside reverse transcriptase inhibitors. Lab Invest 81: 777.
19. Lewis W, et al., 2003. Mitochondrial toxicity of NRTI antiviral drugs: An integrated cellular perspective. Nat Rev Drug Discov 2: 812-822.
20. Livak KJ, Schmittgen TD,. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods 25: 402-408.
21. Mallon PWG, et al., 2005. In Vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 191: 1686-1696.
22. Manda KR, et al., 2011. Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells. Free Radic Biol Med 50: 801-810.
23. Motohashi H, Yamamoto M,. 2004. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 10: 549-557.
24. Nedergaard J, et al., 2005. Uncoupling proteins: Current status and therapeutic prospects. EMBO Rep 6: 917-921.
25. Núñez M,. 2006. Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. J Hepatol 44: S132.
26. Phulukdaree A, et al., 2010. The effects of Sutherlandia frutescens extracts in cultured renal proximal and distal tubule epithelial cells. S Afr J Sci 106: 54-58.
27. Piantadosi CA, et al., 2008. Heme oxygenase-1 regulates cardiac mitochondrial biogenesis via Nrf2-mediated transcriptional control of nuclear respiratory factor-1. Circ Res 103: 1232-1240.
28. Roe AL, et al., 1993. HepG2 cells: An in vitro model for P450-dependent metabolism of acetaminophen. Biochem Biophys Res Commun 190: 15-19.
29. Sambrook J, Russell D D W,. 2001. Molecular cloning: A laboratory manual. New York: Cold Spring Harbour Laboratory Press.
30. Setzer B, et al., 2008. Pyrimidine nucleoside depletion sensitizes to the mitochondrial hepatotoxicity of the reverse transcriptase inhibitor stavudine. Am J Pathol 172: 681-690.
31. St-Pierre J, et al., 2006. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 127: 397-408.
32. Stuart J, et al., 2004. DNA base excision repair activities and pathway function in mitochondrial and cellular lysates from cells lacking mitochondrial DNA. Nucleic Acids Res 32: 2181-2192.
33. Ter Hofstede HJ, et al., 2000. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS 11: 611-616.
34. Valle I, et al., 2005. PGC-1α regulates the mitochondrial antioxidant defense system in vascular endothelial cells. Cardiovasc Res 66: 562-573.
35. Velsor LW, et al., 2004. Mitochondrial oxidative stress in human hepatoma cells exposed to stavudine. Toxicol Appl Pharmacol 199: 10-19.
36. Venhoff N, et al., 2007. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther 12: 1075.
37. Walker UA, et al., 2002. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16: 2165-2173.
38. Wit FW, et al., 2002. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 186: 23-31.
39. Zong H, et al., 2002. AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci 99: 15983-15987.